Background {#Sec1}
==========

Individuals who undergo cardiac surgery with cardiopulmonary bypass (CPB) are often exposed to impaired blood coagulation, both as a result of dysfunction of platelet (PLT) and circulatory system was primed of large volumes of fluid \[[@CR1], [@CR2]\]. Blood coagulation would be theoretically further impaired when cell salvage (CS) was used in this kind of surgery due to its procedure of centrifugation and washing \[[@CR3], [@CR4]\]. However, previous literatures indicated that CS had no impairment on blood coagulation in low-bleeding-risk cardiac surgery with CPB \[[@CR5], [@CR6]\].

High- bleeding-risk cardiac surgery with CPB refers to those surgeries with high risk of bleeding due to patients' poor physical condition and long duration and complexity of the surgery \[[@CR3], [@CR7], [@CR8]\]. Among 1.25 million patients undergoing cardiac surgery all over the world each year, a large proportion is with high-bleeding-risk \[[@CR9]\].The volume of autologous blood transfusion was much larger in high-bleeding-risk cardiac surgeries with CPB than in low-bleeding-risk ones \[[@CR9], [@CR10]\]. Studies demonstrated that volume of autologous blood transfusion was associated with the severity of impairment of blood coagulation \[[@CR11]--[@CR13]\]. We hypothesized that CS could impair blood coagulation when it was used in high-bleeding-risk cardiac surgery.

To date, parameters related to blood coagulation include thromboelastography (TEG) parameters and other hematological parameters such as PLT and FIB. TEG was reported as one of the best indicators of blood coagulation in cardiac surgery with CPB \[[@CR14]--[@CR16]\]. Combination of the test of kaolin-activated sample and the test of heparinase-modified kaolin-activated sample was reported much better to detect heparin residues \[[@CR17], [@CR18]\].

Till now, limited studies existed evaluating the impact of CS on blood coagulation in high-bleeding-risk cardiac surgery with CPB. The aim of this prospective randomized and controlled clinical trial was to fill this gap. The primary endpoint of this trial was the incidence of impairment of blood coagulation during perioperative period (peri-op), which was defined as the period from beginning of anesthesia (anesthesia induction) to 24 h after end of surgery (Fig. [1](#Fig1){ref-type="fig"}). The secondary endpoint was the incidence of adverse events during postoperative period (post-op), which was defined as the period from the end of surgery to 24 h after end of surgery (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1The timeline of events. *T* ~*1*~ 5 min before beginning of surgery, *T* ~*2*~ 5 min after heparin was reversed by protamine, *T* ~*3*~ at the end of surgery, *T* ~*4*~ at 24 h after end of surgery. *Perioperative period* (*peri-op*) the period from beginning of anesthesia to 24 h after end of surgery. *Postoperative period* (*post-op*) the period from the end of surgery to 24 h after end of surgery. The period of heparinization: the period from blood anticoagulated by heparin to heparin were reversed by protamine. The period of non-heparinization: the period from beginning of surgery to blood anticoagulated by heparin + the period from heparin were reversed by protamine to end of surgery

Methods {#Sec2}
=======

Patients {#Sec3}
--------

This study was approved by the Ethics Committee of the Zhejiang Provincial People's Hospital (RCT ID: ChiCTR-TRC-13003268). Patients were enrolled in the study after written informed consent was signed. Inclusion and exclusion criteria were shown in Table [1](#Tab1){ref-type="table"} \[[@CR3], [@CR7], [@CR8]\]. One hundred and ten eligible patients were randomly assigned into two groups according to a randomization list: cell salvage group (Group CS) and control group (Group C). Patients in Group CS were treated with intra-operative CS while those in Group C without.Table 1Inclusion and exclusion criteria of patientsInclusion criteriaExclusion criteriaOpportunity of surgeryScheduled for cardiac surgery with CPBEmergency cardiac surgery with CPBType of surgeryMultiple valves replacementThe first time single valve replacementBentallReoperation (at least 1 item above 3 items must be met)Characteristics of patientAge \>70 yearsBSA \<1.6 m^2^Cr \>15 mg/LLiver Child--Pugh B or CR (TEG) \>10 min;HB \<13 g/dL (male) or 12 g/dL (female)PLT \<50 × 10^9^/LDrug withdrawal \<3 days (Aspirin) or 7 days (Clopidogrel) (at least 2 items above 8 items must be met)Eligible patient must meet opportunity of surgery and type of surgery and characteristics of patient at the same time*Multiple valves replacement* aortic valves replacement + mitral valve replacement*Bentall* aortic valve replacement + ascending aorta and aortic root replacement*Reoperation* not the first time single or multiple valve replacement*BSA* body surface area, *TEG* thromboelastography, *HB* hemoglobin, *PLT* platelets, *Cr* creatinine

CPB {#Sec4}
---

Tranexamic Acid (AMCHA, 30 mg/kg) was infused in all patients after anesthesia induction \[[@CR9]\]. The CPB was performed using a HL20 heart--lung machine (MAQUET, Israel) with an OCTOPUS4 extracorporeal membrane oxygenation (Medtronic, USA). The volume of fluid primed was 1.8 L, the main ingredient was ringer's lactate solution, along with a small amount of albumin and mannitol. Anticoagulation was achieved with heparin to maintain an activated clotting time (ACT) above 480 s. After separation from CPB, heparin was reversed by protamine to a target-ACT of range from 90 to 110 % of base value.

Autologous blood transfusion {#Sec5}
----------------------------

In Group CS, shed blood from wound and mediastina were sucked into the cell saver reservoir (Haemonetics, USA, volume of disposable centrifuge bowl is 125 mL) after anticoagulated by heparin saline during the period of non-heparinization (Fig. [1](#Fig1){ref-type="fig"}). The heparinised saline contain 25,000 IU of heparin in 1 L of 0.9 % saline at a rate of 100 mL/h. At the end of CPB, residual blood in the CPB circuit was directly sucked into the reservoir. After being filtrated, centrifugated, washed and concentrated, the recovered blood turned into autologous blood (autologous red blood cell suspension), which was transfused back to the patient immediately. The washing program used in the CS involved a 5:1 ratio between the 0.9 % saline wash and collection of blood from the operating field. All of the autologous blood was transfused back to the patients by the end of surgery. In Group C, shed blood from wound and mediastina during the period of non-heparinization (Fig. [1](#Fig1){ref-type="fig"}) were sucked into suction apparatus and were discarded. In Group C, at the end of CPB residual blood in the CPB circuit were sucked into suction apparatus and were discarded. Patients' bleeding during the period of heparinization (Fig. [1](#Fig1){ref-type="fig"}) in two groups were sucked into the CPB circuit.

Blood transfusion during peri-op {#Sec6}
--------------------------------

After heparin was reversed by protamine, allogeneic red blood cell (RBC) was used if hemoglobin (HB) was lower than 8 g/dL in Group C \[[@CR3]\]. In Group CS, allogeneic RBC was used only if HB was still lower than 8 g/dL after transfused all of the autologous blood. Allogeneic fresh-frozen plasma (FFP) and PLT transfusion was used during peri-op according to the protocol (showed in the seventh and eighth line in Fig. [2](#Fig2){ref-type="fig"} \[[@CR3], [@CR16], [@CR19]\]. Patients with excessive bleeding during post-op, which was defined as the rate of bleeding greater than 300 mL in the first hour after surgery or greater than 2 mL/kg/h for 3 consecutive hours, were treated according to the same protocol (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2The processing protocol of excessive bleeding during post-op. Once excessive bleeding was diagnosed, patients received treatment based on the results of the tests in the TEG, PLT and FIB. First hour: in the first hour after surgery, hour × 3: for 3 consecutive hours. *TEG* kaolin-activated TEG, *h-TEG* heparinase-modified kaolin-activated TEG, *R* reaction time, *R-TEG* R value in TEG, *R-h-TEG* R value in h-TEG, *MA* maximum amplitude, *LY30* lysis index at 30 min, *PLT* platelets, *FFP* fresh-frozen plasma, *FIB* fibrinogen, *AMCHA* tranexamic acid

Study variables {#Sec7}
---------------

Basal and operative characteristics: including age, gender, BSA, type of surgery, complications, CPB time, surgical time, tracheal intubation time, length of ICU stay, length of hospital stay, the volume of residual blood in CPB circuit, the volume of intra-operative blood loss, the volume of mediastina tube drainage (MTD) in 6 and 24 h after surgery, intra-operative dosage of heparin and protamine. The volume of intra-operative blood loss was calculated as the volume sucked into cell saver reservoir minus the volume of heparin saline for anticoagulation in Group CS or the volume sucked into suction apparatus in Group C.

Volume of blood transfusion during peri-op: including the volume of autogenous blood in Group CS, the volume of allogeneic blood (RBC, PLT and FFP) in two groups.

Hematological parameters during peri-op: including general parameters and parameters related to blood coagulation. General parameters included RBC and HB. Parameters related to blood coagulation included TEG parameters (Haemonetics, USA), PLT and FIB. TEG parameters included R value (R-TEG and R-h-TEG), MA and LY 30. R (reaction time, normal range from 10 to 19 min) represents the time to initiation of clot formation. R-TEG and R-h-TEG are the R value of test of kaolin-activated sample and heparinase-modified kaolin-activated sample, respectively; MA (maximum amplitude, normal range from 54.5 to 72.5 mm) represents the maximum clot strength; LY30 (lysis rate-30, normal range from 0 to 7.5 %) represents the rate of cloth lysis 30 min after MA. Venous blood was tested at the following four time points or anytime when excessive bleeding occurred during post-op: at the time of after anesthesia induction and 5 min before beginning of surgery (T~1~), 5 min after heparin was reversed by protamine during surgery (T~2~), at the end of surgery (T~3~) and at 24 h after end of surgery (T~4~) (Fig. [1](#Fig1){ref-type="fig"}).

Impairment of blood coagulation during peri-op: impairment of blood coagulation was diagnosed according to the test results of hematological parameters related to blood coagulation (showed in the seventh and eighth line in Fig. [2](#Fig2){ref-type="fig"}). Impairment of blood coagulation were classified into five types: heparin residual, coagulopathy due to low PLT (decreasing of PLT results in hypocoagulability), coagulopathy due to low FIB (shortage of FIB results in hypocoagulability), coagulopathy due to low coagulation factors (shortage of other coagulation factors except for factor results in hypocoagulability) and hyperfibrinolytic (showed in the seventh and eighth line in Fig. [2](#Fig2){ref-type="fig"}) \[[@CR17], [@CR19]\]. The sum of above five types was total impairment of blood coagulation.

Adverse events during post-op: including excessive bleeding, resternotomy, cardiovascular failure, severe arrhythmias, myocardial infarction, infection, renal failure, respiratory failure, epileptic syndrome, cognitive decline and death.

Statistical analysis {#Sec8}
--------------------

Data are presented as mean (standard deviation, SD) for continuous parametric values, or as numbers with percentage for categorical data. For continuous data, the two-sample two-sided Student's t test or the Wilcoxon Rank-Sum two-sample two-sided test was used. For categorical data, the *χ*^*2*^ test or Fisher's exact-test was used. Considering some variables may influence relevant clinical outcomes potentially, the logistic regression model was used to analyze the outcomes in Table [4](#Tab4){ref-type="table"}. Odds ratios (ORs) resulting from logistic regression analysis were used to estimate relative risk (RR) ratios. Data analysis was performed using SAS statistical software (version 9.1; SAS Institute Inc., Cary, NC, USA). *P* value of less than 0.05 was considered as statistically significant.

Results {#Sec9}
=======

Basal and operative characteristics {#Sec10}
-----------------------------------

Of the total 110 patients randomized between April 2013 and September 2014, 55 were allocated to Group CS and 55 to Group C (Fig. [3](#Fig3){ref-type="fig"}). There was no difference between two groups in the listed variables (Table [2](#Tab2){ref-type="table"}).Fig. 3CONSORT diagram of flow of patientsTable 2Patients' basal and operative characteristicsVariableGroup CS (n = 53)Group C (n = 50)P valueAge (years)50.42 (15.43)52.53 (15.65)0.549 \>7012 (22.64)13 (26.00)0.691Male27 (50.94)24 (48.00)0.765BSA1.73 (0.14)1.73 (0.13)0.946 \<1.6 m^2^5 (9.43)4 (8.00)1.000Surgery type0.922 Multiple valve36 (67.92)33 (66.00) Bentall8 (15.09)7 (20.00) Reoperations9 (16.98)10 (14.00)Preoperative complication Renal dysfunction19 (35.84)18 (36.00)0.987 Liver insufficiency9 (16.98)7 (14.00)0.676 Coagulation disorders15 (28.30)13 (26.00)0.793 HB levels lower (\<13 g/dL in male or \<12 g/dL in female)21 (39.62)23 (46.00)0.51317 (32.08)18 (36.00)0.674 PLT levels lower (\<50 × 10^9^/L) intake of aspirin or clopidogrel12 (22.53)11 (22.00)0.938CPB time (min)136.05 (36.82)126.65 (25.63)0.342Surgical time (min)302.56 (28.02)295.94 (22.02)0.220Tracheal intubation time (hour)13.92 (10.83)13.15 (3.62)0.434Length of ICU stay (hour)19.42 (4.43)20.42 (4.16)0.099Length of hospital stay (day)22.56 (4.23)23.38 (4.54)0.206Residual blood in CPB circuit853.67 (50.46)837.22 (92.53)0.200Intra-operative blood loss (mL)1640.96 (87.73)1609.03 (137.91)0.072MTD (mL) In 6 h333.02 (147.14)295.03 (152.82)0.301 In 24 h657.78 (272.94)591.96 (171.53)0.071Intra-operative heparin dose (mg)244.63 (49.82)241.06 (49.35)0.778Intra-operative protamine dose (mg)428.37 (92.83)417.36 (92.02)0.478Data are presented as mean (SD) or number (percentage)*MTD* mediastinal tube drainage, patients with resternotomy were not calculated

Blood transfusion during peri-op {#Sec11}
--------------------------------

The mean volume of autologous blood transfusion in Group CS was 4.13 U (0.31 U). The proportion of allogeneic RBC transfusion during peri-op was 41.51 % in Group CS versus 78.00 % in Group C. The mean volume of allogeneic RBC transfusion during peri-op was 2.66 U in Group CS versus 5.40 U in Group C. Both the proportion and volume of allogeneic RBC transfusion during peri-op were significantly lower in Group CS than in Group C (Table [3](#Tab3){ref-type="table"}).Table 3Allogeneic blood transfusion during peri-opVariableGroup CS (n = 53)Group C (n = 50)P valueRBC Proportion22 (41.51)39 (78.00)0.0002 Volume (U)2.11 (2.66)5.40 (3.48)\<0.0001FFP Proportion10 (18.87)9 (18.00)0.910 Volume (mL)118.76 (253.82)129.00 (284.92)0.953PLT Proportion12 (22.64)10 (20.00)0.744 Volume (U)1.81 (3.56)1.92 (3.94)0.916Data are presented as mean (SD) or number (percentage)

Impairment of blood coagulation during peri-op {#Sec12}
----------------------------------------------

The incidences of heparin residual at T~3~ and during post-op were significant higher in Group CS (15.09 and 13.21 %) than in Group C (4.00 and 2.00 %), with *p* value as 0.024 and 0.010, respectively (Fig. [4](#Fig4){ref-type="fig"}). Similarly, the incidences of total impairment of blood coagulation at T~3~ and during post-op were significant higher in Group CS (32.08 and 26.42 %) than in Group C (18.00 and 12.00 %), with *p* value as 0.043 and 0.040, respectively (Fig. [4](#Fig4){ref-type="fig"}). The RR value of CS with heparin residual was 6.10. CS was associated with an increase in the RR for heparin residual (*p* = 0.034) (Table [5](#Tab5){ref-type="table"}).Fig. 4Comparison of impairment of blood coagulation during peri-op between two groups. *x-axis* type of impairment of blood coagulation, *A* heparin residual, *B* coagulopathy for low PLT, *C* coagulopathy for low FIB, *D* coagulopathy for low clotting factors, *E* hyperfibrinolysis, *T* total (A + B + C + D + E). *y-axis* cases of each type, *T* ~*1*~ at the time of after anesthesia induction and 5 min before surgery, *T* ~*2*~ 5 min after heparin was reversed by protamine during surgery, *T* ~*3*~ at the end of surgery, *post-op* during postoperative period, *T* ~*4*~ at the time of 24 h after surgery. \*p = 0.024(T~3~ − A), 0.043(T~3~ − T), 0.010 (post-op − A), 0.040 (post-op − T), respectively

Adverse events during post-op {#Sec13}
-----------------------------

The incidence of excessive bleeding during post-op were significantly higher in Group CS (32.08 %) than in Group C (16.00 %) (Table [4](#Tab4){ref-type="table"}). The RR value of CS with excessive bleeding was 4.58. CS was associated with an increase in the RR for excessive bleeding (*p* = 0.049) (Table [5](#Tab5){ref-type="table"}).Table 4Relationship of CS with impairment of blood coagulation and adverse eventsVariableRR95 % CIP valueHeparin residual6.101.14--32.600.034Coagulopathy for low PLT0.610.14--2.610.509Coagulopathy for low FIB1.350.40--4.480.629Coagulopathy for low clotting factors0.560.09--3.300.521Excessive bleeding4.581.02--18.340.049Myocardial infarction0.150.01--1.990.150Cognitive decline\<0.001\<0.001--999.990.938*RR* relative risk, *CI* confidence intervalTable 5Summary of adverse events during post-opVariableGroup CS (n = 53)Group C (n = 50)P valueExcessive bleeding17 (32.08)8 (16.00)0.038Resternotomy3 (5.66)2 (4.00)1.000Cardiovascular failure6 (11.32)7 (14.00)0.682Severe arrhythmias requiring treatment4 (7.55)3 (6.00)1.000Myocardial infarction1 (1.89)4 (8.00)0.196Infection7 (13.21)6 (12.00)0.948 Wound3 (5.66)2 (4.00)1.000 Others4 (7.55)4 (8.00)1.000Renal failure5 (9.43)4 (8.00)1.000Respiratory failure3 (5.66)2 (4.00)1.000Epileptic syndrome1 (1.89)1 (2.00)1.000Cognitive decline0 (0.00)3 (6.00)0.111Death0 (0.00)0 (0.00)Data are presented as number (percentage)

Discussion {#Sec14}
==========

In our present study, significant differences of the incidence of heparin residues and total impairment of blood coagulation during peri-op were found between two groups. We also found that the incidence of excessive bleeding during post-op was significantly higher in group CS than in group C. In addition, we found that CS was a dependent risk factor for heparin residues and excessive bleeding. These results indicate that intra-operative CS could impair blood coagulation in the scenario of high-risk-bleeding cardiac surgery with CPB, which is consistent with our hypothesis.

CPB determines an activation of the coagulation system \[[@CR1], [@CR2]\]. CS system determines a further activation of the coagulation system \[[@CR3], [@CR4], [@CR20]\]. The enhanced activation of the coagulation system induced a strong thrombin generation. Thrombin generation directly consumes coagulation factors, activates PLT, promotes fibrinolysis, lowers fibrinolysis inhibition and stimulates the release of tissue plasminogen activator from endothelial cells \[[@CR20]\]. These conditions were considered as a possible trigger for a consumption coagulopathy and hyperfibrinolysis.

In our practice, processing of recovered blood during the CS process involves the collection of blood and mixing with heparinised saline, centrifugation of the cells, followed by saline washing prior to re-transfusion to the patient. The washing program used in the CS involved a 5:1 ratio between the 0.9 % saline wash and collection of blood. This process removes plasma proteins and coagulation factors. In addition, hemodilution during CPB and the fluid therapy during post-CPB may result in dilutional coagulopathy \[[@CR12], [@CR21]\].

To prevent thrombogenesis during the collection of blood, as the standard protocol practiced in our study, the heparinised saline containing 25,000 IU of heparin in 1 L of 0.9 % saline at a rate of 100 mL/h was used. Previous studies revealed that after the recovered blood processed by the CS system. The autologous blood may contain heparin about 500 IU/L \[[@CR12]\]. In our study, the incidence of heparin residual at the end of surgery were 15.09 % in Group CS and 4 % in Group C, respectively. This result reveals that residual heparin from the CS system could worsen the coagulopathy and also is an important trigger for the impairment of blood coagulation in these patients.

The dose of heparin in the autologous blood that was transfused back to the patient could vary depends on the transfusion volume, concentration and drip rate of heparinised saline. We found it is very cumbersome in clinical practice to estimate the level of heparin in the autologous blood. Anticoagulation was commonly monitored with ACT. Clinicians would have to use protamine to reverse the residual heparin according to the ACT value. The value of ACT may be prolonged by hemodilution which is very common in this kind of surgery \[[@CR22]\]. Thus, ACT is a partially reliable bedside method for monitoring the adequacy of anticoagulation. Recent studies revealed that the TEG is a more reliable and sensitive method for assessment of the heparinization level after the autologous blood transfusion \[[@CR16], [@CR23]\]. In our study, the R values of heparinase-modified kaolin-activated samples (R-h-TEG) were compared with those of kaolin-activated samples (R-TEG) to assess heparin residual.

The appropriate concentration of the anticoagulant heparin saline and the degree of washing performed by the CS are vital to preventing the heparin residual from the autologous blood. The concentration of the anticoagulant heparin saline used was 50,000 IU/L, even 30,000 IU/L in some report \[[@CR24]\]. In our study, although the concentration 25,000 IU/L and the degree of washing 5:1 volume ratio between the 0.9 % saline wash and blood were used, the incidence of heparin residual at the end of surgery in Group CS was up to 15.09 %. This implies that the concentration of 25,000 IU/L may be still risky \[[@CR22]\]. The solution to this specific problem may be either reducing the concentration of anticoagulant heparin saline or administering an appropriate dose of protamine to reverse heparin depends on the monitoring of TEG. However, reducing the concentration of heparin may result in thrombogenesis during the collection of blood from the operating field. On the other hand, increasing the dose of protamine may cause adverse events such as allergic reactions. Future studies with a large sample size are urgently begged to further evaluate the appropriate concentration of the anticoagulant heparin saline.

Literatures indicated that intra-operative CS has no impairment on blood coagulation in low-bleeding-risk cardiac surgery with CPB \[[@CR5], [@CR6]\]. In our present study, intra-operative CS could impair blood coagulation in the scenario of high-risk-bleeding cardiac surgery with CPB. Previous studies reported that the volume of autologous blood transfused back to the patient in high-bleeding-risk cardiac surgery with CPB was much larger than in low-bleeding-risk cardiac surgery \[[@CR9], [@CR10]\]. All types of impairment of blood coagulation are associated with the volume of autologous blood. The more autologous blood transfused, the more severe the impairment of CS on blood coagulation to be expected.

To the best of our knowledge, our study is the first prospective randomized controlled clinical trial investigating the impact of CS on blood coagulation in high-risk-bleeding cardiac surgery with CPB. As the increasing popularity of the CS, more attention should be focused on the patients' blood coagulation after the autologous blood transfusion, especially in the patients in high-bleeding-risk cardiac surgery with CPB. This study highlighted the importance of the blood coagulation monitoring which could be overlooked in these situations \[[@CR24]\]. We strongly recommend application of monitoring of blood coagulation by the TEG combined with kaolin-activated sample and heparinase-modified kaolin-activated sample. Our experience was valuable for anesthesiologists and surgeons to deal with the impairment of blood coagulation in this kind of surgery.

One limitation of our study was the evaluation standard of high-bleeding-risk cardiac surgery. Because there is no universal standard so far, the standard we employed may need some modification. In addition, double blind research method was not adopted in the present study due to objective reasons, which may include some bias. This protocol may affect our results. Another limitation of present study was the administration of AMCHA which lowers fibrinolysis. Accordingly, the incidence of hyperfibrinolysis in two groups were lower than usual.

Conclusion {#Sec15}
==========

Our preliminary data support a proposal that intra-operative CS could impair blood coagulation in the scenario of high-risk-bleeding cardiac surgery with CPB.

CS

:   cell salvage

CPB

:   cardiopulmonary bypass

Peri-op

:   perioperative period, the period from anesthesia induction to 24 h after surgery

Post-op

:   postoperative period, the period from the end of surgery to 24 h after surgery

TEG

:   thromboelastography, kaolin-activated TEG

h-TEG

:   heparinase-modified kaolin-activated TEG

R

:   reaction time

R-TEG

:   R value in TEG

R-h-TEG

:   R value in h-TEG

MA

:   maximum amplitude

LY30

:   lysis index at 30 min

AMCHA

:   tranexamic acid

ACT

:   activated clotting time

RBC

:   red blood cell

HB

:   hemoglobin

PLT

:   platelets

FIB

:   fibrinogen

FFP

:   fresh-frozen plasma

MTD

:   the volume of mediastina tube drainage

RR

:   relative risk
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